• 1
    Ashworth TR. A case of cancer in which cells similar to those in the tumors were seen in the blood after death. Aust Med J. 1869; 14: 146.
  • 2
    Gallivan MV, Lokich JJ. Carcinocythemia (carcinoma cell leukemia): report of two cases with English literature review. Cancer. 1984; 53: 1100-1102.
  • 3
    Allard WJ, Matera J, Miller MC. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004; 10: 6897-6904.
  • 4
    Chiang AC, Massagué J. Molecular basis of metastasis. N Engl J Med. 2008; 359: 2814-2823.
  • 5
    Méhes G, Witt A, Kubista E, Ambro PD. Circulating breast cancer cells are frequently apoptotic. Am J Pathol. 2001; 159: 17-20.
  • 6
    Meng S, Tripathy D, Frenkel EP, et al. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res. 2004; 10: 8152-8162.
  • 7
    Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351: 781-791.
  • 8
    Andreopoulou E, Lang LY, Rangel KM, et al. Comparison of assay methods for detection of circulating tumor cells (CTCS) in metastatic breast cancer (MBC): AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veriden Cell Search™ system. Int J Cancer. 2011; doi:10.1002/ijc.26111.
  • 9
    Reithdorf S, Pantel K. Advancing personalized cancer therapy by detection and characterization of circulating tumor cells. Ann NY Acad Sci. 2010; 1210: 66-77.
  • 10
    Van Der Auwera I, Peeters D, Benoy IH, et al. Circulating tumour cell detection: a direct comparison between the CellSearch System, the Adna Test and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer. Br J Cancer. 2010; 102: 276-284.
  • 11
    Bostick PJ, Chatterjee S, Chi DD, et al. Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients. J Clin Oncol. 1998; 16: 2632-2640.
  • 12
    Sieuwerts AM, Kraan J, Bolt J, et al. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst. 2009; 101: 61-66.
  • 13
    Punnoose EA, Atwal SK, Spoerke JM, et al. Molecular biomarker analyses using circulating tumor cells. PLoS One. 2010; 5: e12517.
  • 14
    Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007; 20: 1235-1239.
  • 15
    Krishnamurthy S, Bischoff FZ, Mayer JA, et al. Detection of HER2 status of circulating tumor cells and disseminated tumor cells using a microfluidic platform (cell enrichment and extraction technology, CEE™). J Clin Oncol. 2011; 29( suppl). Abstract 613.
  • 16
    Hayes DF, Cristofanilli M, Budd GT, et al. Circulating tumor cells at each following time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006; 12: 4218-4224.
  • 17
    Liu MC, Shields PG, Warren RD, et al. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol. 2009; 27: 5153-5159.
  • 18
    Nakamura S, Yagata H, Ohno S, et al. Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer. Breast Cancer. 2010; 17: 199-204.
  • 19
    Budd GT, Cristofanilli M, Ellis MJ, et al. Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin Cancer Res. 2006; 12: 6403-6409.
  • 20
    Krishnamurthy S, Cristofanilli M, Singh B, et al. Detection of miminal residual disease in blood and bone marrow in early stage breast cancer. Cancer. 2010; 116: 3330-3337.
  • 21
    Ignatiadis M, Kallergi G, Ntoulia M, et al. Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Clin Cancer Res. 2008; 14: 2593-2600.
  • 22
    Rack BK, Schindlbeck C, Hofmann S, et al. Circulating tumor cells (CTCs) in peripheral blood of primary breast cancer patients [abstract]. J Clin Oncol. 2007; 25( 18 suppl): 10595.
  • 23
    Meng S, Tripathy D, Shete S, et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A. 2004; 101: 9393-9398.
  • 24
    Riethdorf S, Müller V, Zhang L, et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res. 2010; 16: 2634-2645.
  • 25
    Fehm T, Müller V, Aktas B, et al. Her2 status of circulating tumor cells in patients with metastatic breast cancer; a prospective multicenter trial. Breast Cancer Res Treat. 2010; 124: 403-412.
  • 26
    Pestrin M, Bessi S, Galardi F, et al. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res Treat. 2009; 118: 523-530.
  • 27
    Munzone E, Nolé F, Goldhirsch A, et al. Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer. Clin Breast Cancer. 2010; 10: 392-397.
  • 28
    Pachman K, Camara O, Kroll T, et al. Efficacy control of therapy using circulating epithelial tumor cells (CETC) as “liquid biopsy”: trastuzumab in HER2/neu-positive breast carcinoma. J Cancer Res Clin Oncol. 2011; 137: 1317-1327.
  • 29
    Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendation for their use of tumor markers in breast cancer. J Clin Oncol. 2007; 25: 5287-5312.
  • 30
    National Cancer Institute. Clinical trials home page. Accessed August 8, 2011.